EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information

Loren Saulsberry iD, Jacob C Jameson iD, Robert D Gibbons, M Eileen Dolan, Olufunmilayo I Olopade, Peter H O'Donnell iD

Clinical Pharmacology & Therapeutics · 2025-06 · 117 (6) · 1793-1802

DOI: 10.1002/cpt.3617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 03.03.2025. Verfasst von Loren Saulsberry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, The University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Pharmacogenetics, Prescription Drugs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHGRI NIH HHS, NIEHS NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tailoring pharmacogenomic (PGx) implementation to diverse populations is vital to promoting health equity. We assessed prescriptions for medications with potentially actionable PGx information to identify patient characteristics associated with differential PGx medication exposure. We analyzed the nationally‐representative MEPS dataset of adults who reported receiving prescriptions between 2014 and 2021. PGx medications include those the FDA and CPIC designate as having drug‐gene associations supported by scientific evidence. With the primary outcome being PGx prescriptions, we performed Poisson regression adjusted for all other relevant covariates. In our final population ( N = 119,722, 72% White/20% Black/4% Asian/8% Hispanic), 61% were prescribed a PGx medication, 56% were female, and 97% held health insurance coverage. Adults with private health insurance (65%) or public Medicaid/Medicare coverage (32%) were more likely to have PGx prescriptions than the uninsured (3%). Individuals with cardiovascular conditions [adjusted IRR (aIRR) = 1.45, 95% CI 1.41, 1.48], high cholesterol [aIRR = 1.37, 95% CI 1.35, 1.40], high blood pressure [aIRR = 1.14, 95% CI 1.12, 1.16], and cancer [aIRR = 1.02, 95% CI 1.00, 1.04] were more likely to receive PGx prescriptions. Self‐reported Blacks were less likely than Whites to receive PGx medications [aIRR = 0.92, 95% CI 0.90, 0.94], and among those with health conditions, the likelihood of PGx medication exposure for underrepresented groups (Blacks, Hispanics, and Asians) was lower than for Whites. Our study using a comprehensive list of PGx medications in a nationally representative dataset indicates that certain populations are differentially exposed to genomically informed medications. This may suggest that if implementing a pharmacogenomics program based on reactive testing initiated by a prescription, a small underrepresentation of the Black population could be expected because of an underlying prescription disparity. Secondly, if implementing a pharmacogenomics program based on targeted preemptive testing, using clinical indication/comorbidity may be a reasonable way to enrich the population for prescriptions that would benefit from genotype tailoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacogeneticsPrescription DrugsHumansFemaleUnited StatesMaleMiddle AgedAdultAgedYoung AdultAdolescentInsurance, HealthInsurance CoveragePharmacogenomic Testing

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Department of Public Health Sciences, The University of Chicago, Chicago, Illinois, USA.
  • Center for Personalized Therapeutics, The University of Chicago, Chicago, Illinois, USA.
  • Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
  • Harvard Kennedy School, Harvard University, Cambridge, Massachusetts, USA.
  • Interfaculty Initiative in Health Policy, Harvard University, Cambridge, Massachusetts, USA.
  • Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Loren Saulsberry, Jacob C Jameson, Peter H O'Donnell

Förderung

  • NHGRI NIH HHS
  • NIEHS NIH HHS
  • NIMH NIH HHS
  • National Human Genome Research Institute

Zitieren

APA

Saulsberry, L., Jameson, J. C., Gibbons, R. D., Dolan, M. E., Olopade, O. I., & O'Donnell, P. H. (2025). A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information. Clinical Pharmacology & Therapeutics, 117(6), 1793-1802. https://doi.org/10.1002/cpt.3617

Vancouver

Saulsberry L, Jameson JC, Gibbons RD, Dolan ME, Olopade OI, O'Donnell PH. A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information. Clinical Pharmacology & Therapeutics. 2025;117(6):1793-1802. doi:10.1002/cpt.3617

BibTeX
@article{Saulsberry2025,
  author = {Saulsberry, Loren and Jameson, Jacob C and Gibbons, Robert D and Dolan, M Eileen and Olopade, Olufunmilayo I and O'Donnell, Peter H},
  title = {A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {6},
  pages = {1793--1802},
  doi = {10.1002/cpt.3617}
}
Kostenlos starten →